
Immunome Market Cap | IMNM
As of November 22, 2026 Immunome has a market cap of $ 1.37 B
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Immunome
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.89 B | 1.27 B | 490 M | 62.3 M | 150 M | 146 M | - | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.89 B | 62.3 M | 667 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
ObsEva SA
OBSV
|
156 M | - | -15.52 % | $ 10.5 M | ||
|
Arrowhead Pharmaceuticals
ARWR
|
6.71 B | $ 41.53 | -4.86 % | $ 5.88 B | ||
|
Monopar Therapeutics
MNPR
|
401 M | $ 69.02 | -1.81 % | $ 512 M | ||
|
Poseida Therapeutics
PSTX
|
306 M | - | - | $ 857 M | ||
|
Y-mAbs Therapeutics
YMAB
|
216 M | - | - | $ 382 M | ||
|
Satsuma Pharmaceuticals
STSA
|
27.2 M | - | -0.9 % | $ 36.5 M | ||
|
Anavex Life Sciences Corp.
AVXL
|
291 M | $ 0.59 | -11.3 % | $ 50.3 M | ||
|
SpringWorks Therapeutics
SWTX
|
4.45 B | - | - | $ 3.48 B | ||
|
Axon Enterprise
AXON
|
30.6 B | $ 291.02 | -5.2 % | $ 22.7 B | ||
|
Infinity Pharmaceuticals
INFI
|
17 M | - | -46.98 % | $ 3.57 M | ||
|
Ayala Pharmaceuticals
AYLA
|
7.72 M | - | - | $ 7.46 M | ||
|
Evelo Biosciences
EVLO
|
27 M | - | -14.46 % | $ 27.9 M | ||
|
Morphic Holding
MORF
|
1.52 B | - | - | $ 2.42 B | ||
|
Genocea Biosciences
GNCA
|
72.7 M | - | -15.0 % | $ 3.04 M | ||
|
Biogen
BIIB
|
29.4 B | $ 249.55 | 0.98 % | $ 36.6 B | ||
|
Bristol-Myers Squibb Company
BMY
|
122 B | $ 58.74 | 0.69 % | $ 119 B | ||
|
Eiger BioPharmaceuticals
EIGR
|
3.11 M | - | -9.21 % | $ 2.55 M | ||
|
IGM Biosciences
IGMS
|
84.7 M | - | - | $ 76.9 M | ||
|
Merrimack Pharmaceuticals
MACK
|
211 M | - | - | $ 216 M | ||
|
Rubius Therapeutics
RUBY
|
11.7 M | - | -33.55 % | $ 7.81 M | ||
|
Mirati Therapeutics
MRTX
|
2.56 B | - | - | $ 3.3 B | ||
|
InVivo Therapeutics Holdings Corp.
NVIV
|
3.15 M | - | -37.48 % | $ 476 K | ||
|
Bellicum Pharmaceuticals
BLCM
|
8.32 M | - | -9.72 % | $ 5.89 M | ||
|
Orchard Therapeutics plc
ORTX
|
672 M | - | 1.02 % | $ 90.8 M | ||
|
La Jolla Pharmaceutical Company
LJPC
|
127 M | - | - | $ 154 M | ||
|
Oyster Point Pharma
OYST
|
312 M | - | - | $ 300 M | ||
|
Intercept Pharmaceuticals
ICPT
|
706 M | - | - | $ 643 M | ||
|
Chinook Therapeutics
KDNY
|
1.39 B | - | - | $ 2.6 B | ||
|
Syros Pharmaceuticals
SYRS
|
165 M | - | -8.44 % | $ 3.4 M | ||
|
NanoViricides
NNVC
|
30.3 M | $ 1.15 | -2.54 % | $ 23.2 M | ||
|
GT Biopharma
GTBP
|
2.59 M | $ 2.93 | -7.86 % | $ 16.2 M | ||
|
Zymeworks
ZYME
|
845 M | $ 26.41 | -1.68 % | $ 1.36 B | ||
|
Aldeyra Therapeutics
ALDX
|
327 M | $ 0.84 | 16.41 % | $ 50.4 M | ||
|
Citius Pharmaceuticals
CTXR
|
8.52 M | $ 0.51 | 1.61 % | $ 5.64 M | ||
|
Cytokinetics, Incorporated
CYTK
|
7.55 M | $ 50.7 | -1.48 % | $ 6.09 M | ||
|
DBV Technologies S.A.
DBVT
|
2.82 B | $ 9.03 | -4.14 % | $ 1.26 B | ||
|
Precision BioSciences
DTIL
|
64.6 M | $ 7.37 | 6.66 % | $ 94.5 M | ||
|
Exelixis
EXEL
|
11.7 B | $ 64.59 | -1.88 % | $ 17.5 B | ||
|
Fennec Pharmaceuticals
FENC
|
169 M | $ 13.09 | -2.68 % | $ 374 M | ||
|
Cardiff Oncology
CRDF
|
116 M | $ 0.85 | -4.67 % | $ 56.8 M | ||
|
BioNTech SE
BNTX
|
22 B | $ 80.87 | -0.63 % | $ 19.5 B | ||
|
Alkermes plc
ALKS
|
5.13 B | $ 44.89 | -2.79 % | $ 7.39 B | ||
|
ANI Pharmaceuticals
ANIP
|
1.24 B | $ 68.6 | -0.77 % | $ 1.38 B | ||
|
AIM ImmunoTech
AIM
|
1.13 M | $ 0.11 | -7.75 % | $ 178 K | ||
|
AC Immune SA
ACIU
|
287 M | $ 1.98 | -7.28 % | $ 199 M | ||
|
Atara Biotherapeutics
ATRA
|
73.6 M | $ 6.51 | 2.6 % | $ 81.7 M | ||
|
Allogene Therapeutics
ALLO
|
545 M | $ 0.63 | -5.62 % | $ 139 M | ||
|
Altimmune
ALT
|
318 M | $ 1.33 | -6.03 % | $ 117 M | ||
|
AnaptysBio
ANAB
|
1.59 B | $ 46.65 | -1.58 % | $ 1.35 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
28.9 M | - | -1.52 % | $ 24.7 M |